德国特应性皮炎注册登记TREATgermany患者基线特征、疾病严重程度与治疗史
TREATgermany注册登记由德国皮肤病学会于2011年发起,旨在评估中重度特应性皮炎患者的真实医疗状况。该中期分析纳入612例中重度特应性皮炎患者,基线时疾病负担显著,多数患者已使用或处方度普利尤单抗,提示仍需替代治疗以改善生活质量。
要点
- 中重度特应性皮炎患者疾病负担显著,瘙痒评分最高。
- 基线时度普利尤单抗为最常用生物制剂,当前使用12.1%,处方31.4%。
- 超过60%患者曾接受系统性糖皮质激素,36.8%曾用环孢素A。
核心结论
- 真实世界数据显示中重度特应性皮炎患者疾病负担显著,多数患者基线时已使用或处方度普利尤单抗,亟需替代治疗以改善生活质量。
研究设计与样本
- 多中心前瞻性注册登记研究,纳入612例年龄≥18岁的中重度特应性皮炎患者,来自32个中心,2016年6月至2019年1月入组,随访至少24个月。
主要发现
- 患者平均年龄42.6±14.2岁,平均oSCORAD为40.8±16.3,平均POEM评分为16.3±7.5。
- 瘙痒在主观症状中评分最高,NRS为5.4±2.7;平均DLQI为11.3±7.5。
- 高血压频率为20.8%,低于一般人群;抑郁症频率为10%,高于一般人群。
- 超过60%的患者入组前曾接受系统性糖皮质激素,36.8%曾接受环孢素A。
- 基线时度普利尤单抗为记录最多的当前使用(12.1%)或处方(31.4%)药物。
临床怎么用
- 真实世界数据提示中重度特应性皮炎患者疾病负担重,临床应关注瘙痒及生活质量改善。
- 度普利尤单抗是基线时最常用的生物制剂,但部分患者仍需其他替代治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Atopic Dermatitis (AD) TREATgermany registry was initiated by the German Society for Dermatology (DDG) in 2011 to evaluate the 'real-life' situation of health care for patients with AD. OBJECTIVES: Interim data analysis on baseline characteristics as well as current and prescribed systemic treatments of the TREATgermany registry patients. METHODS: Patients (≥18 years) with moderate-to-severe AD [objective (o)SCORAD > 20], or with current or previous anti-inflammatory systemic treatment for AD within 24 months, were included and are followed up over at least 24 months. To assess clinical signs, the eczema area severity index (EASI, 0-72), the oSCORAD (0-83) and the Investigator Global Assessment (IGA; 6-point scale) were used. The disease severity was globally scored by the patients [Patient Global Assessment (PGA); six-step Likert scale]. Disease symptoms were assessed by the patient-oriented eczema measure (POEM, 0-28) and numeric rating scales (NRS, 0-10). Health-related quality of life was measured using the dermatological life quality index (DLQI, 0-30). RESULTS: A total of 612 patients were recruited across 32 sites between 06/2016 and 01/2019 (mean age: 42.6 ± 14.2 years; mean oSCORAD: 40.8 ± 16.3). The mean POEM score was 16.3 ± 7.5. Pruritus was rated highest among subjective symptoms (NRS: 5.4 ± 2.7). The mean DLQI value was 11.3 ± 7.5. The frequency of arterial hypertension was lower (20.8%) compared with the general population, whilst this was higher for depression (10%). More than 60% of the patients had received systemic glucocorticosteroids, and 36.8% had received cyclosporine A prior to inclusion. Dupilumab was the leading substance documented as either 'current' (12.1%) or 'prescribed' (31.4%) at baseline. CONCLUSIONS: These 'real-life' data clearly demonstrate the substantial disease burden. Most of TREATgermany patients were already treated with or prescribed dupilumab at baseline. Moreover, current findings indicate the urgent need for further alternative agents in order to achieve a perceptible improvement of quality of life of patients with moderate-to-severe AD.
引用
- Heratizadeh A, Haufe E, Stölzl D, et al. Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany. J Eur Acad Dermatol Venereol. 2020. PMID: 31721316. doi:10.1111/jdv.16078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。